Disease · MONDO_0001187
Comparisons in its trials20
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 20
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Apaziquone vs Placebo: deaths from any cause | 14 of 402 | 14 of 410 | 812 | NCT00598806 | Trial comparisons |
| Apaziquone vs Placebo: serious adverse events | 96 of 402 | 108 of 410 | 812 | NCT00598806 | Trial comparisons |
| Apaziquone vs Placebo: deaths from any cause | 11 of 406 | 13 of 396 | 802 | NCT00461591 | Trial comparisons |
| Apaziquone vs Placebo: serious adverse events | 93 of 406 | 98 of 396 | 802 | NCT00461591 | Trial comparisons |
| Pelvic RT + Paclitaxel + Cisplatin vs Pelvic RT + Fluorouracil + Cisplatin: serious adverse events | 43 of 46 | 39 of 47 | 93 | NCT00055601 | Trial comparisons |
| Melanoma Cancer Patients vs Bladder Cancer Patients: deaths from any cause | 2 of 10 | 51 of 69 | 79 | NCT02553642 | Trial comparisons |
| Melanoma Cancer Patients vs Bladder Cancer Patients: serious adverse events | 10 of 10 | 69 of 69 | 79 | NCT02553642 | Trial comparisons |
| Infigratinib 125 mg vs Placebo: Number of Participants With Serious Adverse Events (SAEs) | 2 of 20 | 2 of 19 | 39 | NCT04197986 | Trial comparisons |
| Infigratinib 125 mg vs Placebo: Number of Participants With Adverse Events (AEs) | 19 of 20 | 16 of 19 | 39 | NCT04197986 | Trial comparisons |
| Infigratinib 125 mg vs Placebo: deaths from any cause | 2 of 20 | 1 of 19 | 39 | NCT04197986 | Trial comparisons |
| Infigratinib 125 mg vs Placebo: serious adverse events | 2 of 20 | 2 of 19 | 39 | NCT04197986 | Trial comparisons |
| CVA21 vs CVA21/Mitomycin C: Incidence of Dose-limiting Toxicities Treatment-related Adverse Events. | 9 of 9 | 6 of 6 | 15 | NCT02316171 | Trial comparisons |
| CVA21 vs CVA21/Mitomycin C: deaths from any cause | 0 of 9 | 0 of 6 | 15 | NCT02316171 | Trial comparisons |
| CVA21 vs CVA21/Mitomycin C: serious adverse events | 1 of 9 | 0 of 6 | 15 | NCT02316171 | Trial comparisons |
| Intravenous MK-3475-100 mg/ Intravesical BCG vs Intravenous MK-3475-200 mg/ Intravesical BCG: deaths from any cause | 0 of 3 | 3 of 10 | 13 | NCT02324582 | Trial comparisons |
| Intravenous MK-3475-100 mg/ Intravesical BCG vs Intravenous MK-3475-200 mg/ Intravesical BCG: serious adverse events | 0 of 3 | 6 of 10 | 13 | NCT02324582 | Trial comparisons |
| 0.06 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine vs 0.08 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine: deaths from any cause | 2 of 9 | 1 of 3 | 12 | NCT01625260 | Trial comparisons |
| 0.06 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine vs 0.08 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine: serious adverse events | 3 of 9 | 1 of 3 | 12 | NCT01625260 | Trial comparisons |
| Intravenous MK-3475-100 mg/ Intravesical BCG vs Intravenous MK-3475-200 mg/ Intravesical BCG: Number of Participants Without Bladder Tumors Upon Cystoscopy Following Treatment. | 2 of 3 | 6 of 9 | 12 | NCT02324582 | Trial comparisons |
Phase 1b: Eribulin Mesylate 0.7 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2 vs Phase 1b: Eribulin Mesylate 1.0 mg/m^2 + Gemcitabine 1000 mg/m^2 + Cisplatin 70 mg/m^2: Phase 1b: Number of Participants With Dose-limiting Toxicity (DLT) as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 | 0 of 3 | 1 of 6 | 9 | NCT01126749 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001187/comparisons